Carnosine for Peripheral Arterial Disease Patients

Description

Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.

Conditions

Peripheral Arterial Disease

Talk to us

Study Overview

On this page

Study Details

Study overview

Oral supplementation of L-carnosine will increase muscle carnosine, stabilize HIF1-alpha promote angiogenesis, and thus improve the functioning of lower extremities in PAD patients.

Carnosine for Peripheral Arterial Disease Patients (Car-PAD)

Carnosine for Peripheral Arterial Disease Patients

Condition
Peripheral Arterial Disease
Intervention / Treatment

-

Contacts and Locations

Louisville

University of Louisville, Louisville, Kentucky, United States, 40202

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Male subjects more than \>50 to \<80 years of age.
  • 2. White or African American race.
  • 3. English Speaking.
  • 4. ABI 0.4-\< 0.60
  • 5. Willing to comply with protocol requirements.
  • 6. Able to provide informed consent. -
  • 1. Subjects with HIV, hepatitis, significant liver disease, active infection, anemia, organ transplant, renal disease requiring dialysis, lung disease requiring oxygen, significant congenital heart disease, cancer of any type, and untreated thyroid disease.
  • 2. Diagnosis of carnosinemia.
  • 3. Known allergy to L-carnosine or meat.
  • 4. Presence of a pacemaker.
  • 5. Obesity from a known genetic defect.
  • 6. Dementia.
  • 7. Critical limb ischemia with below or above knee amputations.
  • 8. Foot ulcers.
  • 9. Major amputations.
  • 10. Participating in other clinical trials.
  • 11. End stage renal disease.
  • 12. Presence of significant injury within 30 days before enrollment.
  • 13. Prisoners.
  • 14. Any metallic implants.
  • 15. Poorly controlled diabetes (HbA1C \>9%) -

Ages Eligible for Study

50 Years to 80 Years

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Shahid Baba,

Study Record Dates

2024-12-30